BVT Call 130 MRK 17.01.2025/ DE000VG1NR35 /
2025-01-15 10:20:39 AM | Chg.+0.100 | Bid11:53:47 AM | Ask11:53:47 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.180EUR | +9.26% | 1.180 Bid Size: 24,000 |
1.190 Ask Size: 24,000 |
MERCK KGAA O.N. | 130.00 EUR | 2025-01-17 | Call |
GlobeNewswire
2024-06-03
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
2024-05-29
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
2024-05-29
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire
2024-05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
2024-05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
2024-03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA